Evropska unija - slovenščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - rekombinantne turčija herpesvirus, sev vhvt013-69, v živo - immunologicals za aves, domačo kokošjo, immunologicals - embryonated eggs; chicken - za aktivno imunizacijo piščancev:Če želite preprečiti, umrljivost in zmanjšati klinični znaki in poškodb nalezljivih bolezni bursal. za zmanjšanje umrljivosti, klinični znaki in poškodbah marek je bolezen.

Evropska unija - slovenščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease virus, serotype 1, strain rn1250; live recombinant turkey herpesvirus, expressing the vp2 protein of infectious bursal disease virus, strain vhvt013-69 - immunologicals for aves, domestic fowl, avian herpes virus (marek's disease) + avian infectious bursal disease virus (gumboro disease) + newcastle disease virus/paramyxovirus - piščanec - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus), and to prevent mortality, clinical signs and lesions caused by infectious bursal disease (ibd) virus.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

roche d.o.o. - dornaza alfa, rekombinantna - inhalacijska raztopina za nebulator - dornaza alfa, rekombinantna 1 mg / 1 ml - dornaza alfa (dezoksiribonukleaza)

Evropska unija - slovenščina - EMA (European Medicines Agency)

virbac s.a. - rekombinantni omega interferon mačjega izvora - immunostimulants, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. pri mačkah, okuženih s fiv, je bila smrtnost nizka (5%) in na zdravljenje ni vplivala.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pfizer luxembourg sarl - somatropin, rekombinantni - prašek in vehikel za raztopino za injiciranje - somatropin, rekombinantni 5,3 mg / 1 vložek - somatropin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pfizer luxembourg sarl - somatropin, rekombinantni - prašek in vehikel za raztopino za injiciranje - somatropin, rekombinantni 12 mg / 1 vložek - somatropin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

eli lilly farmacevtska druŽba, d.o.o. - somatropin, rekombinantni - prašek in vehikel za raztopino za injiciranje - somatropin, rekombinantni 12 mg / 1 vložek - somatropin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pfizer luxembourg sarl - somatropin, rekombinantni - prašek in vehikel za raztopino za injiciranje - somatropin, rekombinantni 12 mg / 1 vložek - somatropin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

eli lilly farmacevtska druŽba, d.o.o. - somatropin, rekombinantni - prašek in vehikel za raztopino za injiciranje - somatropin, rekombinantni 24 mg / 1 vložek - somatropin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

roche d.o.o. - interferon alfa-2a, rekombinantni - raztopina za injiciranje - interferon alfa-2a, rekombinantni 4500000 i.e. / 0,5 ml - interferon alfa-2a